ASCO 2020：11项中国研究表现出色口头报告，17项Poster报告

受全球另行冠非典型肺炎影响，提前于5月29日~6月2日在纽约举行的美国临床学会（ASCO）年会今年将首次以线上型式举办，这是目前为止最大规模的线上盛会。时至今日，大会的概述题目公布，共103个sessions，中会国共有11项数据深入研究入选口头报告，17项入选Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

吡咯替尼或希亚替尼加卡培他鹿岛用做HER2+结核乳腺恶性肿突起（PHOEBE）：一项III期随机试验持续性。

艺术节：结核乳腺恶性肿突起

所作：中会国医学科学院病房徐兵河数据深入研究员、马飞数据深入研究员，复旦大学附属病房胡夕春数据深入研究员等

概述号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可切除三阴持续性乳腺恶性肿突起新标准用药后卡培他鹿岛延续节拍放射治疗的III期试验持续性（SYSUCC-001）。

艺术节：乳腺恶性肿突起—周围内/周围/专门设计用药

所作：中会山大学防治中会心三王树森数据深入研究员等

概述号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

利用结核脑的环境因素特征来数据深入研究脑脊液中会循环DNA验证的概率: 另行机器压制据说对手

艺术节：另行机器解决据说问题

所作：李美芹 李德兰等

概述号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

利诺非尼对比索拉非尼作为更早肝细胞内恶性肿突起的主力用药：一项闭馆标签、随机、多中会心II/III期试验持续性。

艺术节：肺肠道恶性肿突起—肺十二指肠、肝脏和自是

所作：西安交通大学华西病房毕锋数据深入研究员、中会国当权者解放军双十病房秦叔逵数据深入研究员等

概述号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

中会国更早肝恶性肿突起患儿阿帕替尼防区用药：一项随机、抗抑郁药对照、双盲III期数据深入研究

艺术节：肺肠道恶性肿突起—肺十二指肠、肝脏和自是

所作：中会国当权者解放军双十病房秦叔逵数据深入研究员、西安交通大学华西病房李秋数据深入研究员等

概述号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

更早罹患持续性肺恶性肿突起二次细胞内减灭术的一项随机III期试验持续性：SOC1 / SGOG-OV2。

讲座：诊疗恶性肿突起症

所作：复旦大学附属中会山病房臧荣余数据深入研究员等

概述：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈恶性肿突起根治持续性子宫切除后专门设计用药中会的序贯放放射治疗对比原则上PET或同步放放射治疗（STARS数据深入研究）：一项随机、对照、闭馆标签的III期试验持续性。

大会：诊疗恶性肿突起症

所作：中会山大学防治中会心马尔季尼夫卡数据深入研究员、刘继红数据深入研究员等

概述号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：专门设计吉非替尼对比放射治疗用做可切除的EGFR凋亡的N1-N2期NSCLC-随机III期临床试验持续性的最终总体适应环境深入研究。

讲座：肺恶性肿突起—非小细胞内周围内-周围/小细胞内/其他胸部

所作：广东省当权者病房吴一龙数据深入研究员等

概述号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR凋亡若无转移非小细胞内肺恶性肿突起患儿主力酪氨酸激酶胺合组或不合组积极前线周围内PET：III期闭馆标签临床随机试验持续性（SINDAS）的中会期结果（NCT02893332）。

讲座：肺恶性肿突起-非小细胞内转移

所作：四川省当权者病房曾铭数据深入研究员等

概述：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对程序持续性失踪-1（PD-1）的人源化IgG4酵母菌合组阿昔替尼用做结核呼吸道黑色素突起患儿的Ib期数据深入研究的总适应环境期和海洋生物一个大深入研究。

讲座：黑色素突起/皮肤恶性肿突起

所作：北京大学病房郭军、盛锡楠数据深入研究员等

概述：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的有效持续性和结果：通用CAR-T细胞内首次消化系统试验持续性用药罹患/难治持续性T细胞内急持续性红细胞内白血病（r/r T-ALL）的有效持续性和。大会：开发计划中会的用药技术-免疫用药。所作：三王欣欣等概述：3013剧照：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利他汀在更早十二指肠鳞状细胞内恶性肿突起患儿中会的运用：一项随机的闭馆标签II期试验持续性（ORIENT-2）。大会：肺肠道恶性肿突起-肺十二指肠恶性肿突起、肝脏恶性肿突起和自是道恶性肿突起所作：徐建明数据深入研究员等概述：4511剧照：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D特异持续性CAR-T细胞内对髓母细胞内突起的造成危害持续性用药大会：周围神经所作：代红久、孙斌、杨东、徐晖、朱晶晶、魏佳、郑旭东概述：2522剧照。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在更早错配修复缺陷患儿中会的运用大会：开发计划中会的用药学-免疫用药所作：沈琳数据深入研究员等概述：3021剧照。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 自体CD7-CART用药罹患/难治持续性ACUTE红细胞内白血病/淋巴突起的首例消化系统临床试验持续性大会: 开发计划持续性用药学-免疫用药所作简介：张明志，白水等概述：3026剧照: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 雷利替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度胺（T）合组运用做更早实体突起患儿的Ib期数据深入研究大会：发展持续性用药学--分子靶向本品和分子海洋生物学所作：龚继芳，沈琳数据深入研究员等概述：3523剧照：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin合组紫杉醇和nedaplatin用药罹患持续性或结核十二指肠鳞状细胞内恶性肿突起（ESCC）患儿的II期数据深入研究。大会：肺肠道恶性肿突起-肺十二指肠、肝脏和自是道恶性肿突起的数据深入研究所作：三王志极强，李玉红，三王德申，三王凤华，任超，谭琼 三王志极强、李玉红、三王德深、三王凤华、任超、谭琼概述：4522剧照：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.大会：肺肠道恶性肿突起-肺十二指肠恶性肿突起、肝脏恶性肿突起和自是管恶性肿突起的防区用药所作：宋艳等概述：4524剧照：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种尿液外体网状RNA权重用做初始活检时验证高等级恶性肿突起的尿液外体网状RNA权重：一项多中会心的回顾持续性数据深入研究大会：泌尿生殖系统恶性肿突起症---恶性肿突起、睾丸恶性肿突起和恶性肿突起所作简介：Liaoyuan Li等概述：5522剧照。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 周围内更早宫颈恶性肿突起并发放射治疗后的专门设计放射治疗大会: 诊疗恶性肿突起症所作简介： 李珉珉等概述：6031剧照：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼用药甲状腺髓持续性恶性肿突起的相关持续性：基于ALTER01031试验持续性的深入研究。会话：外周所作：天津市病房霸道数据深入研究员概述：6526剧照。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、大小和年龄对安洛替尼用药后患儿第一集的影响: ALTER01031的亚组深入研究大会：外周所作：天津市病房霸道数据深入研究员概述：6527剧照。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA深入研究数据深入研究I-IIIA期非小细胞内肺恶性肿突起（NSCLC）患儿术后罹患: GASTO1035和GASTO1018的结果大会：肺恶性肿突起-非小细胞内周围内-国际持续性/小细胞内/小细胞内/其他胸科恶性肿突起症所作：Si-Yu Wang等概述：9023剧照：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小细胞内肺恶性肿突起（NSCLC）中会EGFR酪氨酸激酶胺的另行型致病功能大会:肺恶性肿突起-非小细胞内结核肺恶性肿突起所作简介：郑昕，金艾利，满宇，欧春花，梅氏，薛武，杨少，范敏 郑昕、金艾利、满宇、欧春花、梅氏、薛武、杨绍、范敏概述：9528剧照：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1试验持续性世纪之交黑色素突起总适应环境的替代起点大会：黑色素突起/皮肤恶性肿突起所作：聂润聪，袁书极强，李元芳，陈英波，周志伟 聂润聪、袁书极强、李元芳、陈英波、周志伟概述：10030剧照：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼用药罹患或结核原发持续性恶持续性骨患儿的II期数据深入研究大会： 肉突起所作：唐丽娜，牛晓辉，三王震，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、三王振、蔡启庆、涂崇奇、范正福、杨瑶概述：11525剧照。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 初步评价安罗替尼在更早肉突起患儿多线用药中会的有效持续性和。大会：肉突起所作：姚伟涛，三王家极强，玑，三王欣，杜另行辉，田志浩，牛晓颖 姚伟涛、三王家极强、玑、三王鑫、杜鑫辉、田志超、牛晓英概述：11526剧照：414